Recently EGFR tyrosine kinase inhibitors (EGFR TKIs) and immune checkpoint inhibitors (ICIs) have demonstrated improvements in DFS in the adjuvant setting among patients with resectable NSCLC.
Herbst of the Medical Oncology, Yale School of Medicine and Yale Cancer Center in New Haven, CT, US and colleagues on 31 January 2023 in the Journal of Clinical Oncology. The prolonged DFS benefit over placebo, magnitude of DFS benefit, reduced risk of local and distant recurrence, improved central nervous system (CNS) DFS, and consistent safety profile observed in this updated analysis support adjuvant osimertinib as a highly effective treatment in patients with resected EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC). Adjuvant osimertinib demonstrated a sustained clinically meaningful DFS benefit, consistent with primary reporting, with DFS benefit observed across all subgroups and stages defined. In updated analysis of the final, mature disease-free survival (DFS) data of the ADAURA study, all 682 patients had the opportunity of 3 years of treatment 66% and 41% patients completed 3 years of planned adjuvant osimertinib and placebo treatment.
0 kommentar(er)
